Topic:

Sales and Marketing

Latest Headlines

Latest Headlines

Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers

Bristol-Myers Squibb and Otsuka won't have to fight claims that they promoted Abilify for off-label uses or used kickbacks to persuade doctors to prescribe the antipsychotic drug. A U.S. judge tossed out those allegations, leveled by a couple of whistleblowers in 2011, for lack of specific evidence.

Report: Pet owners clueless about obesity in their cats and dogs

A new survey finds an astonishing "fat pet gap" in the U.S. According to the study, 58% of cats and 53% of dogs were overweight last year. Yet more than 90% of these pets' owners incorrectly identified their four-legged friends as normal weight.

Dr. Reddy's shopping for deals up to $1B as it expands in injectable meds

Dr. Reddy's Laboratories is looking to expand its market footprint, eyeing as much as $1 billion in potential deals and higher-end products like generic injectable drugs to chart growth and diversify its offerings.

Cipla revs up for generic Sovaldi launch in India

Cipla is rolling out a low-cost version of Gilead Sciences' hep C powerhouse Sovaldi in India, the latest company to launch a copycat of the drug as part of Gilead's deal with generic drugmakers to provide Sovaldi at cut-rate prices.

Which diseases are driving drug spending hikes? It's not just hep C

Industry watchers well know that U.S. drug spending is rising--a lot. And they also know that it's likely to continue over the next few years if some major changes don't occur. But which medical conditions will be responsible for the swelling tide? Some of those may surprise you.

Novo Nordisk unloads autoimmune project to Bristol-Myers

Novo Nordisk, in the process of exiting autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.

Daiichi shells out $200M-plus to help AstraZeneca launch Movantik

AstraZeneca has decided not to go it alone on marketing Movantik. Daiichi Sankyo has signed on to help launch the constipation pill--and it's paying a pretty penny for the opportunity.

Pernix figures 1 + 1 + 1 equals more than three with new Zohydro salesforce

Pernix Therapeutics is looking for a sales trifecta from the 100 new Zohydro reps it's acquiring along with that pain drug franchise.

Gilead to require proof of citizenship to buy Sovaldi in poor countries

Not long after Gilead Sciences' high-priced hep C super drugs Sovaldi, and then combo drug Harvoni, hit the market, the California drugmaker struck deals with 11 generic drugmakers to make cut-rate versions available, and affordable, in 91 developing countries. But Gilead is not as generous as it might seem, Doctors Without Borders claims.

Hep C meds cost-effective, but affordable? With new 46% discounts, maybe

When hepatitis C drugmakers started wooing payers with discounts, the cost cuts made the difference between an overwhelming burden and cost-effective spending. So say two new studies looking at the cost of treating the disease with a new generation of quite effective--but very expensive--treatments.